The sale is pre-planned (options exercise) and moderate in size relative to market cap. Watch for actual Form 4 filings post-execution to confirm completion. No immediate catalyst; likelihood of a block trade affecting price is low given the small relative size.
IRON drugs
IRON drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 22 $70.80entry
- T+1 · 5mo ago −0.49%α +0.96% · $70.45
- T+5 · 5mo ago +5.62%α +7.69% · $74.78
- T+20 · 4mo ago +7.56%α +7.70% · $76.15
- T+60 · 2mo ago −4.94%α −6.69% · $67.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director John Quisel filed a Form 144 notice of intent to sell 34,000 shares of Disc Medicine (IRON), valued at approximately $2.39M based on the filing date. The shares are from the exercise of stock options, and the sale is planned as a cash transaction through Morgan Stanley. While a $2.39M sale by a director is notable, it is not an executive-chair-level event and may be part of routine portfolio diversification.
Key Facts
- Director John D. Quisel filed a Form 144 on June 18, 2026, signaling intent to sell 34,000 shares.
- The estimated aggregate value of the proposed sale is $2,387,140 (based on shares × price on filing date).
- Shares are from the exercise of stock options, not direct open-market accumulation.
- The sale would represent a small fraction of Quisel's total holdings (the filing references total securities outstanding of 38,199,089 shares, but Quisel's personal holdings are not disclosed in this filing).
- Recent insider activity on IRON: one other sell totaling $801K in the prior 30 days, with no buys.
Financial Impact
$2.39M proposed sale by a director, representing approximately 0.09% of the company's $2.7B market cap.
Risk Factors
- Insider selling ahead of potential clinical data readouts or regulatory decisions could signal lack of conviction; however, there is no evidence of such timing here.
- If the sale is completed and followed by additional director sales, it may indicate increasing insider distribution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006325 |
| Document: 0001950047-26-006325-index.html | 0001950047-26-006325 |
| Document: 0001950047-26-006325.txt | 0001950047-26-006325 |
Track record
43 reports on IRON
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers